Barriers to Proper Genetic Testing? Understanding FISH Access

Multiple myeloma patients need a genetic test called FISH (Fluorescence In Situ Hybridization) to help doctors create the best treatment plan. This test looks at the DNA in your cancer cells to identify specific genetic changes that can affect how your disease might progress and which treatments might work best.

Think of FISH testing as taking a close-up picture of your cancer cell's DNA. This detailed view helps your doctor:

• Predict how aggressive your multiple myeloma might be
• Choose the most effective treatment options
• Determine if you qualify for specific clinical trials

A study by Amy Pierre, MSN, and researchers from Flatiron Health, involving over 13,500 multiple myeloma patients, found that some patients face challenges accessing FISH testing based on where they live.

The study identified two main factors: language barriers and transportation issues. Patients in neighborhoods with limited English proficiency were less likely to receive the test, and those in areas with fewer vehicle owners had more difficulty accessing it.

The findings, presented at the ASH 2024 meetings, emphasize how social and environmental factors can hinder access to crucial cancer tests. The researchers recommend healthcare systems address these barriers by improving language support and transportation to ensure all multiple myeloma patients can access vital testing.

If you have multiple myeloma and haven't received FISH testing, talk to your healthcare team about whether this test is right for you. Ask about available resources if you need help with transportation or translation services. Many healthcare systems offer support services to help overcome these barriers to care.

To keep reading more myeloma news like this, click here: HealthTree Myeloma News

Our myeloma newsletter can help you stay informed about your healthcare.

Subscribe Today